Contrasting Prestige Consumer Healthcare (NYSE:PBH) & DiaSorin (OTCMKTS:DSRLF)

Prestige Consumer Healthcare (NYSE:PBH) and DiaSorin (OTCMKTS:DSRLF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Valuation & Earnings

This table compares Prestige Consumer Healthcare and DiaSorin”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.14 billion	2.73	$214.60 million	$4.26	14.81
DiaSorin	$1.28 billion	N/A	$203.55 million	N/A	N/A

Prestige Consumer Healthcare has higher earnings, but lower revenue than DiaSorin.

Institutional & Insider Ownership

100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 1.4% of Prestige Consumer Healthcare shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Prestige Consumer Healthcare and DiaSorin, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	1	3	3	0	2.29
DiaSorin	0	1	2	0	2.67

Prestige Consumer Healthcare currently has a consensus price target of $93.33, suggesting a potential upside of 47.89%. Given Prestige Consumer Healthcare’s higher probable upside, research analysts clearly believe Prestige Consumer Healthcare is more favorable than DiaSorin.

Volatility & Risk

Prestige Consumer Healthcare has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, DiaSorin has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500.

Profitability

This table compares Prestige Consumer Healthcare and DiaSorin’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	19.02%	12.69%	6.79%
DiaSorin	N/A	N/A	N/A

Summary

Prestige Consumer Healthcare beats DiaSorin on 9 of the 11 factors compared between the two stocks.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

About DiaSorin

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.